Pollinex sales nothing to sneeze at for Allergy

A BUMP in sales of vaccines for hay fever sent shares in Aim-listed Allergy Therapeutics up 17pc.

The treatment, Pollinex, can vaccinate patients against the allergy, which flares up in summer, through a short course of four-to-six injections, the company says, and is proving popular in mainland Europe.

Growth in sales of Pollinex helped revenues rise by almost a third to £64.1m for the year to June, up from £48.5m the previous year and ahead of market expec- tations. The jump in revenue would have been 15pc at constant currency, without the impact of the strong euro compared with the weaker pound. Shares in the company closed at 30.1p.

Allergy Therapeutics’ other products include vaccines for bee and wasp stings and dust mites. It is also working on a potential blockbuster vaccine for peanut allergy. The company’s full-year results will be announced in September.